Benjamin P. Levy, MD

Benjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.

Benjamin P. Levy, MD, discusses the role of biomarkers in the treatment landscape for patients with lung cancer.

Benjamin P. Levy, MD, discusses the evolution of molecular drivers in non–small cell lung cancer over the last few years and which testing should be included in patients.

Benjamin P. Levy, MD, discusses the evolution of liquid biopsies in all solid tumors, especially in non–small cell lung cancer (NSCLC) where they are used routinely.

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing on&nbsp;<em>ROS1&nbsp;</em>and&nbsp;<em>TRK&nbsp;</em>mutations.

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the unique adverse events with immunotherapy agents and how physicians can work together to overcome these challenges.

Benjamin P. Levy, MD, discusses how Myriad&#39;s myPlan addresses the risk of recurrence in lung cancer.

Benjamin P. Levy, MD, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.

Benjamin P. Levy, MD, comments on the role of chemotherapy in the treatment of lung cancer.